Q2 2026 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) launched its oncology business on August 15, marking a significant expansion into the oncology sector.
- The company reported strong double-digit growth in both pediatric vaccines and shingles vaccines.
- Specialty business, including products like Nucala and Trelegy, grew by over 20%, indicating robust performance in the respiratory area.
- Despite external market challenges, the company maintained competitive performance with brands performing better than the market.
- EBITDA improved to 34.4%, a 250 basis point increase, driven by strong cost savings and gross margin improvements.
- The company experienced a 2.6% decline in sales, attributed to a fire at a CMO and GST transitionary impacts.
- The acute segment growth was below 5%, impacting therapy areas like anti-infectives and pain management.
- Supply chain issues due to a fire at a CMO resulted in a significant impact on top-line revenue, with a loss of over 40 crores.
- Employee expenses declined by 8.4% year-on-year, partly due to a one-off reversal of provisions, raising concerns about sustainability.
- The general medicines business faced headwinds, leading to a flat performance for the quarter.
Hi, good evening, everyone. This is Dhawin Dias, your moderator from Chorus Call. Welcome to the GlaxoSmithKline Pharmaceuticals Limited Q2 FY 2026 conference.
From the management of GlaxoSmithKline Pharmaceuticals Limited, we have with us Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited; and Mr. Juby Chandy, Chief Financial Officer, GlaxoSmithKline Pharmaceuticals Limited.
By participating in this event, you consent to the recording, distribution, and publication of this event. Kindly note that this call is meant for investors and analysts only. All participant lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation from management concludes.
I now hand the conference over to Mr. Bhushan Akshikar. Thank you and over to you, sir.
Thank you very much, Down. Once again, a very good afternoon to all the ministers and analysts on this Q2 call. I want to begin
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
